J&J Opens New Science & Technology Campus

Johnson & Johnson has opened its San Francisco Bay Campus, more than doubling the R&D presence of the company in the Bay area. The opening of the campus, according to the company, will bridge key scientific and technological capabilities by co-locating Jansson R&D, Johnson & Johnson Innovation, and Johnson & Johnson Technology.

“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions,” said Joaquin Duato, CEO, Johnson & Johnson. “On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”

The facility is nearly 200,000 sq ft and will house up to 400 employees. Additionally, building on the company’s commitment to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus. The new site’s aim is to receive Silver Leadership in Energy & Environmental Design (LEED) certification, known as the most widely used green building rating system in the world.

The campus’ R&D focus spans Janssen’s therapeutic areas and key functions, including emerging science and technology in gene and RNA therapies, treatments and approaches for retinal and infectious disease, and advanced data science. Advanced data will be focused on artificial intelligence and machine learning. Co-locating these institutions, according to the company, will help the expand its discovery engine and industry-leading pipeline. The convergence will also increase its focus on the Johnson & Johnson Technology organization to enhance innovative digital solutions in human health and increase collaboration with Johnson & Johnson Innovation to continue to facilitate investments and early-stage healthcare innovation with academic and industry partners.

“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop, and deliver innovative medicines faster and more efficiently,” said James Merson, PhD, site head, San Francisco Bay campus and global therapeutic area head, infectious diseases, Janssen Research & Development. “By integrating drug discovery, data science, and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide.”